Inflammation pathway molecular target

The term 'Inflammation pathway molecular target' refers to a broad and heterogeneous group of proteins, enzymes, and signaling molecules that mediate the body's inflammatory response (StatPearls, 2023). This category is not a single therapeutic target but rather a collection of distinct molecular entities including cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6), enzymes like Cyclooxygenase-2 (COX-2), and transcription factors like Nuclear Factor-kappa B (NF-kB) (Nature Reviews Drug Discovery, 2017). These targets play critical roles in both acute and chronic inflammation, and their dysregulation is central to the pathogenesis of numerous conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma (PubMed, 2021). Pharmacological intervention typically involves the use of small molecules or biologics designed to inhibit specific components of these pathways to alleviate symptoms and prevent tissue damage (NIH, 2022). Because this term encompasses many different biological systems, therapeutic strategies and safety profiles vary significantly depending on the specific molecule being targeted (Frontiers in Pharmacology, 2020). Consequently, while these targets are essential for therapeutic development, the term itself describes a functional network rather than a single druggable protein (Cell, 2019). Common drugs targeting these pathways include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and monoclonal antibodies (PubChem, 2023). Monitoring efficacy often involves measuring systemic biomarkers like C-reactive protein or specific cytokine levels (Journal of Immunology, 2022).

Other names

Inflammatory signaling targetsMediators of inflammationPro-inflammatory molecular targetsInflammatory cascade targets

Inhibition of cyclooxygenase enzymes, blockade of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6), inhibition of Janus kinases, and modulation of transcription factor activity (e.g., NF-kB).